MedTrace Logo

A Study of GQ1010 in Subjects With Advanced Solid Tumors

NCT06464055 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-02-10

No results posted yet for this study

Summary

This is an open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

Dose Escalation

Drug: GQ1010

DRUG

Dose Expansion1

Drug: GQ1010 dose 1

DRUG

Dose Expansion2

Drug: GQ1010 dose 2

DRUG

Dose Expansion3

Drug: GQ1010 dose 3

DRUG

phase II

Drug: GQ1010 RP2D

Sponsors & Collaborators

  • GeneQuantum Healthcare (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-23
Primary Completion
2028-05-23
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06464055 on ClinicalTrials.gov